Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 12Phase 1 10Phase 1/2 9Phase 2/3 3Phase NA 2

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Thoracic 1

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Nasopharyngeal Carcinoma 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Virus Diseases 1Urethral Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Liver Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Gemcitabine × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Lumos Pharma

Phase 2/3 Terminated
135 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡